X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs SANOFI INDIA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD SANOFI INDIA BIOCON LTD/
SANOFI INDIA
 
P/E (TTM) x 96.0 40.1 239.4% View Chart
P/BV x 8.1 8.6 94.1% View Chart
Dividend Yield % 0.1 1.0 13.6%  

Financials

 BIOCON LTD   SANOFI INDIA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
SANOFI INDIA
Dec-16
BIOCON LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1884,560 26.1%   
Low Rs3054,400 6.9%   
Sales per share (Unadj.) Rs68.71,028.5 6.7%  
Earnings per share (Unadj.) Rs7.6129.0 5.9%  
Cash flow per share (Unadj.) Rs14.0186.0 7.5%  
Dividends per share (Unadj.) Rs1.0068.00 1.5%  
Dividend yield (eoy) %0.11.5 8.8%  
Book value per share (Unadj.) Rs86.3753.6 11.5%  
Shares outstanding (eoy) m600.0023.03 2,605.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.4 249.4%   
Avg P/E ratio x98.934.7 284.6%  
P/CF ratio (eoy) x53.424.1 221.8%  
Price / Book Value ratio x8.65.9 145.4%  
Dividend payout %13.252.7 25.1%   
Avg Mkt Cap Rs m447,900103,174 434.1%   
No. of employees `0006.13.6 169.7%   
Total wages/salary Rs m9,3113,592 259.2%   
Avg. sales/employee Rs Th6,705.86,537.7 102.6%   
Avg. wages/employee Rs Th1,514.2991.4 152.7%   
Avg. net profit/employee Rs Th736.9819.8 89.9%   
INCOME DATA
Net Sales Rs m41,23423,686 174.1%  
Other income Rs m2,062708 291.2%   
Total revenues Rs m43,29624,394 177.5%   
Gross profit Rs m8,2915,281 157.0%  
Depreciation Rs m3,8511,313 293.3%   
Interest Rs m61515 4,100.0%   
Profit before tax Rs m5,8874,661 126.3%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,691 92.8%   
Profit after tax Rs m4,5312,970 152.6%  
Gross profit margin %20.122.3 90.2%  
Effective tax rate %26.736.3 73.5%   
Net profit margin %11.012.5 87.6%  
BALANCE SHEET DATA
Current assets Rs m41,48615,673 264.7%   
Current liabilities Rs m21,4136,678 320.6%   
Net working cap to sales %48.738.0 128.2%  
Current ratio x1.92.3 82.6%  
Inventory Days Days6476 84.2%  
Debtors Days Days9422 422.1%  
Net fixed assets Rs m50,6618,098 625.6%   
Share capital Rs m3,000230 1,302.6%   
"Free" reserves Rs m48,80817,088 285.6%   
Net worth Rs m51,80817,356 298.5%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89725,400 393.3%  
Interest coverage x10.6311.7 3.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.9 44.3%   
Return on assets %5.211.8 43.8%  
Return on equity %8.717.1 51.1%  
Return on capital %9.626.9 35.8%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m12,0587,145 168.8%   
Fx outflow Rs m7,3486,846 107.3%   
Net fx Rs m4,710299 1,575.3%   
CASH FLOW
From Operations Rs m6,6213,226 205.2%  
From Investments Rs m-6,840-1,555 439.9%  
From Financial Activity Rs m-2,397-1,818 131.8%  
Net Cashflow Rs m-2,612-147 1,776.9%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Related Views on News

BIOCON LTD Surges by 5%; BSE HEALTHCARE Index Up 1.8% (Market Updates)

Sep 25, 2018 | Updated on Sep 25, 2018

BIOCON LTD share price has surged by 5% and its current market price is Rs 701. The BSE HEALTHCARE is up by 1.8%. The top gainers in the BSE HEALTHCARE Index is BIOCON LTD (up 5.0%). The top losers are ABBOTT INDIA and J.B.CHEMICALS (down 0.3%).

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 25, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS